Apimeds Pharmaceuticals与LŌKahi Therapeutics联合宣布，已与美国食品药品监督管理局（FDA）就Lt‑100（Apitox）药物安排C类会议。此次会议标志着该候选药物研发进程迈出关键一步。
C类会议通常旨在解决药物开发过程中的特定问题，为后续临床研究或上市申请提供指导。两家公司通过此次会议寻求与FDA就Lt‑100的开发策略进行深入沟通。
Apimeds Pharmaceuticals与LŌKahi Therapeutics联合宣布，已与美国食品药品监督管理局（FDA）就Lt‑100（Apitox）药物安排C类会议。此次会议标志着该候选药物研发进程迈出关键一步。
C类会议通常旨在解决药物开发过程中的特定问题，为后续临床研究或上市申请提供指导。两家公司通过此次会议寻求与FDA就Lt‑100的开发策略进行深入沟通。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.